EDWARDS LIFESCIENCES CORPORATION

(EW)
  Report
Delayed Nyse  -  05/19 04:00:02 pm EDT
94.37 USD   +1.03%
05/19Opsens Presents Results of First-in-human Study of SavvyWire at European Conf
MT
05/17Citigroup Adjusts Price Target on Edwards Lifesciences to $115 From $134, Reiterates Buy Rating
MT
05/16Edwards announces key events for europcr 2022
PR
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Edwards Lifesciences Corporation Receives FDA Approval for SAPIEN 3 with Alterra Prestent for Transcatheter Pulmonic Valve Replacement

12/20/2021 | 09:05am EDT

Edwards Lifesciences Corporation announced it received approval from the U.S. Food and Drug Administration (FDA) for the use of the Edwards SAPIEN 3 transcatheter valve with the Alterra adaptive prestent (SAPIEN 3 with Alterra) for patients with severe pulmonary regurgitation. The Edwards SAPIEN 3 Transcatheter Pulmonary Valve (TPV) system combines the proven SAPIEN 3 transcatheter heart valve and the Alterra adaptive prestent to expand transcatheter therapy options for congenital heart valve disease patients. The Alterra prestent compensates for variations in size and morphology of the right ventricular outflow tract to provide a stable landing zone for the SAPIEN 3 valve. While pulmonic heart valve replacements represent a small fraction of the heart valve replacements done each year, it is generally required to replace valves in adolescent and adult patients suffering from Tetralogy of Fallot or other congenital heart valve defects. The Edwards SAPIEN 3 TPV system with Alterra adaptive prestent is indicated for use in the management of pediatric and adult patients with severe pulmonary regurgitation as measured by echocardiography, who have a native or surgically repaired right ventricular outflow tract and are clinically indicated for surgical pulmonary valve replacement.


© S&P Capital IQ 2021
All news about EDWARDS LIFESCIENCES CORPORATION
05/19Opsens Presents Results of First-in-human Study of SavvyWire at European Conf
MT
05/17Citigroup Adjusts Price Target on Edwards Lifesciences to $115 From $134, Reiterates Bu..
MT
05/16Edwards announces key events for europcr 2022
PR
05/11INSIDER SELL : Edwards Lifesciences
MT
05/04EDWARDS LIFESCIENCES CORP : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
04/29INSIDER SELL : Edwards Lifesciences
MT
04/28EDWARDS LIFESCIENCES CORP Management's Discussion and Analysis of Financial Condition ..
AQ
04/28TRANCHE UPDATE ON EDWARDS LIFESCIENC : EW)'s Equity Buyback Plan announced on May 5, 2021.
CI
04/28TRANCHE UPDATE ON EDWARDS LIFESCIENC : EW)'s Equity Buyback Plan announced on May 8, 2019.
CI
04/27Canaccord Genuity Adjusts Edwards Lifesciences' Price Target to $137 from $152, Keeps B..
MT
More news
Analyst Recommendations on EDWARDS LIFESCIENCES CORPORATION
More recommendations
Financials (USD)
Sales 2022 5 734 M - -
Net income 2022 1 558 M - -
Net cash 2022 1 316 M - -
P/E ratio 2022 38,2x
Yield 2022 -
Capitalization 58 675 M 58 675 M -
EV / Sales 2022 10,0x
EV / Sales 2023 8,77x
Nbr of Employees 15 700
Free-Float 96,5%
Chart EDWARDS LIFESCIENCES CORPORATION
Duration : Period :
Edwards Lifesciences Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EDWARDS LIFESCIENCES CORPORATION
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 24
Last Close Price 94,37 $
Average target price 125,90 $
Spread / Average Target 33,4%
EPS Revisions
Managers and Directors
Michael A. Mussallem Chairman & Chief Executive Officer
Scott B. Ullem Chief Financial Officer & Vice President
Todd J. Brinton Chief Scientific Officer & VP-Advanced Technology
Nicholas J. Valeriani Independent Director
Kieran Thomas Gallahue Independent Director
Sector and Competitors
1st jan.Capi. (M$)
EDWARDS LIFESCIENCES CORPORATION-27.16%58 675
THERMO FISHER SCIENTIFIC-18.74%212 239
DANAHER CORPORATION-24.22%174 392
INTUITIVE SURGICAL, INC.-39.29%77 301
SIEMENS HEALTHINEERS AG-17.17%65 558
BOSTON SCIENTIFIC CORPORATION-7.04%57 512